Capricor to pursue clinical program for treatment of Duchenne muscular dystrophy.
LOS ANGELES, Calif., October 6, 2014 -- Capricor Therapeutics, Inc. (CAPR) said it plans to develop a clinical program for Duchenne muscular dystrophy (DMD) using CAP-1002, its lead product candidate.
CAP-1002 is an allogeneic, off-the-shelf, investigational cell therapy derived from donor heart tissue and is infused directly into a patient's coronary arteries during a catheterization procedure. CAP-1002 is in Phase 2 clinical testing for adults with ischemic heart disease.
The clinical program will move forward based, in part, on data findings from the laboratory of Eduardo Marban of Capricor and the Cedars-Sinai Heart Institute.
The data will be presented at the American Heart Association's Scientific Sessions on November 17th, 2014.
Duchenne muscular dystrophy is a genetic disorder caused by a mutation of the dystrophin gene and is characterized by progressive muscle degeneration and weakness.
Symptoms usually appear in male children before age six but may be visible in early infancy and the disorder is often fatal.
|Printer friendly Cite/link Email Feedback|
|Publication:||Stem Cell Business News|
|Date:||Oct 6, 2014|
|Previous Article:||Kadimastem reports to FDA on results of preclinical ALS treatment studies.|
|Next Article:||Final patient treated in Stargardt's macular degeneration phase 1 trial in U.K.|